ARVO 2026 runs May 3–7 in Denver
- Roche and Ora used the final days before ARVO 2026 to preview what they’ll bring to Denver — turning the meeting into a retinal-data watchpoint. - Roche said it will present more than 45 abstracts, including 20 oral talks across five retinal diseases, while Ora is adding seven Blind Canvas stories. - That matters because ARVO often sets the near-term agenda for ophthalmology — what clinicians discuss next and what investors watch next.
Eye research conferences can sound abstract. But ARVO is one of the places where future eye drugs, imaging tools, and surgical ideas first become legible to the rest of the field. This year’s meeting runs May 3 through May 7 in Denver, and the real news right now is not that the doors are opening — it’s who is using the run-up to plant flags. Roche and Ora both did that this week, with Roche teeing up a big retinal data package and Ora pairing trial-methods research with a patient-story project built around blindness. (arvo.org) ### Why does ARVO matter so much? ARVO is the big annual gathering for eye and vision science — researchers, clinicians, trainees, device people, drug developers, and contract research groups all in one place. The official meeting pages frame it as the main educational and networking forum in the field, and Denver’s convention calendar pegs attendance around 11,000. Basically, if a company wants to shape th(arvo.org)ths, this is one of the cleanest stages to do it. (arvo.org) ### What actually changed this week? The useful shift is that the pre-meeting teasers got specific. Roche published its ARVO curtain-raiser on April 30, saying it will bring more than 45 abstracts and 20 oral presentations. Ora followed with its own preview, laying out trial-design work, a new video series called *Eye to Market*, and fresh Blind Canvas Project material timed to the meeting. So the vague “wa(arvo.org)ed programs and numbers attached. (roche.com) ### What is Roche trying to show? Roche’s pitch is breadth plus staying power in retinal disease. The company says the ARVO package spans five retinal conditions and includes new real-world data for Vabysmo in neovascular age-related macular degeneration and diabetic macular edema, plus data for Susvimo as a continuous-delivery option meant to reduce treatment burden. In plain English —(roche.com)rtfolio story with both injection and implant angles. (roche.com) ### Why do Vabysmo and Susvimo matter? Because retinal care is still dominated by a brutal tradeoff — strong disease control usually means frequent visits and repeated injections. Vabysmo matters when it shows better retinal drying or durability. Susvimo matters when it suggests patients can stay controlled with fewer treatment encounters because the drug is delivered continuously throu(roche.com)attleground in retina right now. (roche.com) ### What is Ora doing differently? Ora is not trying to outgun big pharma on headline efficacy data. Its ARVO story is more about the machinery around ophthalmology trials — endpoints, imaging, study execution, and commercialization handoff. But it is also pushing something softer and, honestly, smarter than it sounds: the Blind Canvas Project, which adds seven storytellers’ interviews (roche.com)ence environment that can get very technical, very fast. (markets.financialcontent.com) ### Is this only about two companies? Not at all. Other biotech groups are also using the week before ARVO to spotlight upcoming presentations, including Alkeus on Stargardt disease data and Beacon Therapeutics on retinal gene-therapy work. That tells you the broader pattern — ARVO is functioning as a launchpad for both established retinal franchises and earlier-stage programs that need attention from specialists. (markets.businessinsider.com) ### So what should people watch in Denver? Watch for two things. First, whether the retinal updates change the durability-versus-burden conversation in a meaningful way. Second, whether the most memorable material comes from classic efficacy tables or from better framing of patient experience, trial design, and adoption. Conferences like this often look like poster marathons from the outside, but the real output is a new pecking order of ideas. (arvo.org) ### Bottom line ARVO 2026 starts on May 3, but the scene-setting already happened. Roche is arriving with scale, Ora is arriving with a systems-and-patients angle, and the meeting now looks less like a generic annual conference and more like a concentrated readout on where ophthalmology wants to go next. (roche.com)
